A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Status:
Not yet recruiting

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).

Phase 1/Phase 2

Theseus Pharmaceuticals